Mucopolysaccharidosis (MPS)
Conditions
Keywords
MPS II, iduronate-2-sulfatase, Mucopolysaccharidosis VI, MPS, MPS VI, ear, nose and throat, Mucopolysaccharidosis II, Hunter syndrome, ENT, Mucopolysaccharidosis I, Hurler, Hurler-Scheie, or Scheie syndrome, Mucopolysaccharidosis, MPS I, Maroteaux-Lamy syndrome
Brief summary
Mucopolysaccharidosis (MPS) type II (MPS II; Hunter syndrome) is a rare, X-linked disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S) and occurs almost exclusively in boys, with an incidence of approximately 1.3 per 100,000 live male births.1 Early identification of MPS II is challenging because some initial features, such as chronic runny nose, otitis media, and hernias, are commonly seen in the general population. As a result, even though the signs and symptoms of MPS II typically appear early in childhood, the diagnosis may lag behind by several years. The primary objective of this international multi-center study is to evaluate the positive screening rate of MPS II subjects by screening a high-risk male pediatric population who have had or are scheduled for 1 or more specific ENT surgical procedures (adenoidectomy and/or tonsillectomy and/or tympanostomy) and who have a previously repaired or present evidence of an inguinal and/or umbilical hernia.
Detailed description
With evidence-based information from MPS registries regarding the types of surgical interventions that are most prevalent in MPS, this screening study is expected to provide the understanding of the role pediatric ENT surgeons can play in identifying young children with MPS.
Interventions
None listed
Sponsors
Shire
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
No minimum to 7 Years
Healthy volunteers
No
Inclusion criteria
Each subject must meet the following criteria to be enrolled in this study: 1. The subject is male. 2. The subject is \<7 years of age. 3. The subject has had or is scheduled for ENT surgery for any of the following, alone or in combination: adenoidectomy, tonsillectomy, and tympanostomy. 4. The subject has record of previous surgical repair or presence of inguinal and/or umbilical hernia. 5. The subject's parent(s) or the subject's legally authorized representative(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
Exclusion criteria
Subjects who meet any of the following criteria will be excluded from the study: 1. The subject has a current confirmed diagnosis of any MPS disorder. 2. The subject was born prematurely (defined as born before 37 weeks gestation). 3. The subject has received a blood transfusion within the past 6 weeks. 4. The subject has received a bone marrow transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The status of diagnosis of MPS II (either positive or negative) of each subject | Screening visit | To evaluate the positive screening rate of MPS II subjects by screening a high risk male pediatric population. |
Secondary
| Measure | Time frame |
|---|---|
| The status of diagnosis of MPS I or VI (either positive or negative) of each subject | Screening visit |
Countries
Canada, Italy, Mexico, Spain, Turkey (Türkiye), United Kingdom, United States
Outcome results
None listed